Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. - Wikidata - wikimedia - TriplyDB

Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.

Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.

http://www.wikidata.org/entity/Q33865839

about

Optimal combination of antiangiogenic therapy for hepatocellular carcinoma Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Gemcitabine and cisplatin-based combination chemotherapy in advanced hepatocellular carcinoma: An Indian experience Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis.Hepatocellular carcinoma: management of an increasingly common problem Palliative oncology: thalidomide.Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives.Molecular targeted therapy for advanced hepatocellular carcinoma

P2860

Q26799458-8478560E-9486-4C40-AC69-61C2740BB2E1 Q27693179-333E9ABF-746C-40E9-8544-E7CE1D183BD7 Q30479629-90813BDE-0074-4516-8233-CA00B17CA57F Q33402113-69990D5E-4099-4E11-9C4E-37E5C6FC11F8 Q36344688-AB9840B1-B888-4CCE-9FF1-7F7D5ED77A0D Q36746503-27DDB35A-DC1E-4C3F-963E-0F67670B98C0 Q37618475-4155F17D-7B71-4C1C-8B73-394FDCBF7BC6 Q37766798-D5EAB761-A536-4E3D-B905-A99F207D1CBC Q58215232-62EE4F85-FB51-4DB9-833A-6514234B350E

P2860

Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.

http://www.wikidata.org/entity/Q33865839

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.

@ast

Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.

@en

type

label

Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.

@ast

Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.

@en

prefLabel

Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.

@ast

Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.

@en

P1433

Q33865839-E296CFAC-9858-4391-A139-D714CEBC8469

P1476

Q33865839-DC14DFDE-20D4-42D3-B5B6-90E87A2F52BD

P2093

Q33865839-14D13423-62C0-4E45-A1B5-C2CF6B960AC6

Q33865839-29F7B381-E4A1-45B5-81CD-D5113A135F03

Q33865839-2A32030D-F336-410B-9387-A14867DD78F0

Q33865839-80D7171B-6FD9-4DFB-99C9-B6FC6816EE2C

P2860

Q33865839-0584343D-DA27-4B8A-AF86-BBFCE02CCC85

Q33865839-13137152-EF85-47C6-AE0A-8CF403323BD5

Q33865839-16A93EC5-3973-4108-B743-0FEF6AC69C14

Q33865839-1F2EAD9F-B183-4C88-BC36-679B755324D0

Q33865839-23D4BD67-3C59-4AE5-BFFE-5C4C213E04B4

Q33865839-3A346D29-E2F8-4C03-9B47-AE2F9CAD1796

Q33865839-41844EDF-8629-483C-85F2-CA4A8F3453F9

Q33865839-6581E3B4-3BBD-4D95-B2A0-2DA0CF5D3874

Q33865839-8317F97C-FBAE-4815-AC81-924E6B3EDC52

Q33865839-86BB405E-FE9A-40C5-8DB5-924EECD49FAC

P304

Q33865839-C6D62907-B944-44B9-AC9E-10B467EBC319

P31

Q33865839-91A6C674-0568-466B-AADE-7D8DD86A3155

P356

Q33865839-8DA5349C-65EA-48F8-AAD0-D7A141C41D86

P407

Q33865839-DB9EBA25-9547-4512-A69A-7D3EA87087A3

P433

Q33865839-4EE17B4E-7A35-4F70-95A8-6728401B38C4

P478

Q33865839-9084B32C-14E8-42DD-B543-8401D1D4758E

P577

Q33865839-23BC7250-C268-4B77-96D5-0731134191C7

P5875

Q33865839-DF9568AC-2DE7-4F3A-9A4C-274C78EBA93E

P698

Q33865839-F44924EA-4EA8-43AE-9191-69F8C7EE9CE8

P921

Q33865839-1538B053-9141-4C72-8FBB-1156911A44DF

P932

Q33865839-C0C3C2EF-D5A0-4F14-9F1A-B14CE644782B

P356

WJG.V12.I43.6955

P1433

World Journal of Gastroenterology

P1476

Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.

@en

P2093

Hsueh-Erh Chiou

http://www.w3.org/2001/XMLSchema#string

Hui-Wen Liu

http://www.w3.org/2001/XMLSchema#string

Tsang-En Wang

http://www.w3.org/2001/XMLSchema#string

Ying-Yue Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Thalidomide is an inhibitor of angiogenesis

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Hepatocellular carcinoma

Thalidomide in cancer medicine.

Potential novel uses of thalidomide: focus on palliative care.

Thalidomide: emerging role in cancer medicine.

Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum.

New drugs for treatment of multiple myeloma.

Salvage therapy for hepatocellular carcinoma with thalidomide.

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.

P304

6955-6960

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V12.I43.6955

http://www.w3.org/2001/XMLSchema#string

P407

P433

43

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

298735906

http://www.w3.org/2001/XMLSchema#string

P698

17109516

http://www.w3.org/2001/XMLSchema#string

P921

P932

4087338

http://www.w3.org/2001/XMLSchema#string